Aston Martin: off to the races

(Full access for Members only)

Image: Roland Woon / Shutterstock.com

Aston Martin: off to the races

28 February 2023

What readers said about this report

Aston Martin is one of the world's most iconic car brands. It created what is indisputably one of the most famous cars in cinematic history, and one of the most desired cars of its time.

Building on its past glory, the company has no lesser ambition but to turn itself into "the most desirable ultra-luxury British performance brand".

However, following a disastrous five years after the company went public in 2018 and had to be rescued to by Canadian billionaire entrepreneur, what are the chances of this to happen?

The market has lost faith in the British carmaker. It's been quite a few years since the company surprised its investors on the upside.

Can Aston Martin prove them wrong?

My latest report:

  • Looks into the track record of the new lead investor.
  • Crunches the company's numbers for the years 2023-2025.
  • Reveals why there may be a few surprises along the way.

It contains everything you need to know about the company and its stock.

If you are interested in iconic car brands and investing, this report is a MUST-read.

Not a Member yet? Sign up for a Membership - just USD 49/year.
Already a Member? Log into your account to download the report.

|  What readers said about this report

Ákos V.
March 2023

What a brave call, rarely can be seen such a sudden blow up, with perfect timing. Many thanks for the Aston Martin Lagonda idea.

Martin B.
March 2023

You have really discovered an undervalued pearl with Aston Martin this time. Respect!

Robert H.
February 2023

Interesting company, thank you! I had already asked myself several years ago why mights such as Toto Wolff take money in their hands and buy shares in Aston Martin.

Most recent

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.